Stay updated on Tisotumab Vedotin in Cervical Cancer Clinical Trial

Sign up to get notified when there's something new on the Tisotumab Vedotin in Cervical Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tisotumab Vedotin in Cervical Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has expanded to include 53 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.2%
    Check dated 2024-07-23T14:47:13.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T08:06:16.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T12:57:25.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T09:23:29.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T08:25:12.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Revision: v2.9.0' has been updated to 'MedlinePlus related topics: Cervical Cancer Drug Information available for: Tisotumab vedotin FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Single arm tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W) Drug : tisotumab vedotin All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity Other Names: TIVDAK'. This change reflects updated information related to the clinical trial on tisotumab vedotin in cervical cancer patients.
    Difference
    99%
    Check dated 2024-06-25T08:06:28.000Z thumbnail image

Stay in the know with updates to Tisotumab Vedotin in Cervical Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tisotumab Vedotin in Cervical Cancer Clinical Trial page.